PF-07081532 is the first clinical candidate from multi-target drug discovery collaboration to advance into Phase 2 trials Dosing of first subject in Phase 2 trial by Pfizer triggers payment of US$10 million to Sosei Heptares Sosei Group Corporation the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, has been notified by Pfizer that the first subject in a Phase 2 clinical trial has been dosed with Pfizer
